3D Systems’ Co-founder & Chief Technology Officer, Chuck Hull, Awarded National Medal of Technology and Innovation
October 26 2023 - 7:30AM
Today, 3D Systems (NYSE:DDD) announced Charles (Chuck) Hull, its
co-founder and chief technology officer for regenerative medicine,
has received the National Medal of Technology and Innovation
(NMTI). Established in 1980, the NMTI is the United States’ highest
honor for technological achievement, awarded by the President of
the United States for outstanding contributions to America’s
economic, environmental, and social well-being. Mr. Hull is
being honored for the invention, development, and commercialization
of Stereolithography (SLA), which launched the 3D printing
industry, and for continuing innovation and leadership in additive
manufacturing technology. He received the honor from President
Joseph Biden at a ceremony held at The White House on Tuesday,
October 24, 2023.
Mr. Hull was Vice President of Engineering at UVP, Inc. (now
owned by Analytik Jena), a company that manufactures ultraviolet
light sources for industrial and scientific applications when he
began working on a way to fuse UV resins into three-dimensional
structures to create product prototypes. In 1983, he produced the
first 3D-printed part, an eye wash cup, using Stereolithography.
Mr. Hull applied for a patent for this technology, and in 1986 he
co-founded 3D Systems through which the SLA-1, the first 3D
printer, was commercialized. With the founding of 3D Systems, he
initiated the 3D printing industry.
In 2014, Mr. Hull was inducted into the National Inventors Hall
of Fame at the United States Patent and Trademark Office for his
globally impactful and transformative work inventing and pioneering
3D printing. The same year, he received the European Patent
Office’s prestigious European Inventor Award in the non-European
countries category for his contributions to technological progress
and the advancement of society. In 2016 Mr. Hull received the
Manufacturing Leadership Lifetime Achievement Award from Frost
& Sullivan’s Manufacturing Leadership Council, and The American
Society of Mechanical Engineers (ASME) honored him and named the
SLA-1, the first commercial 3D printer, a Historic Mechanical
Engineering Landmark. He also received The Economist’s prestigious
2013 Innovation Award, recognizing significant contributions across
the fields of science and technology. Mr. Hull is a named inventor
on 85 United States patents, plus numerous other patents around the
world in the fields of ion optics and 3D printing.
3D Systems remains a leader in innovation with state-of-the-art
production 3D printers, materials, software, and application
experts that have changed how products are manufactured and
healthcare is delivered. As 3D Systems’ Chief Technology Officer
for Regenerative Medicine, Mr. Hull continues to bring his
pioneering spirit to the next frontier of 3D printing —
bioprinting. He leads the 3D Systems team collaborating with United
Therapeutics in a joint development program to establish an
unlimited supply of human lungs, requiring no immunosuppression,
potentially allowing patients with end-stage lung disease to
benefit from an unlimited supply of tolerable, transplantable
organs.
“On behalf of the entire company, I congratulate Chuck as a
recipient of the National Medal of Technology and Innovation,” said
Dr. Jeffrey Graves, president & CEO, 3D Systems. “He has had a
remarkable career with his efforts not only changing the trajectory
of manufacturing but also impacting the human condition by changing
how healthcare is delivered. Chuck’s invention of Stereolithography
gave birth to an industry and since that time, the number of 3D
printing technologies has proliferated, as have the applications
for which they are used. Advancements in applications such as
satellites, electric vehicles, medical implants, dental aligners,
chip manufacturing, carbon capture — 3D printing is playing an
integral role in each one — all made possible by Chuck taking the
first step with SLA. I’m inspired by his passion and believe we’ll
see the possibility of bioprinted human organs becoming a reality
in his lifetime. It’s a pleasure to collaborate with Chuck and I am
so very grateful and privileged to call him a colleague and
friend.”
Forward-Looking StatementsCertain statements
made in this release that are not statements of historical or
current facts are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
performance or achievements of the company to be materially
different from historical results or from any future results or
projections expressed or implied by such forward-looking
statements. In many cases, forward-looking statements can be
identified by terms such as "believes," "belief," "expects," "may,"
"will," "estimates," "intends," "anticipates" or "plans" or the
negative of these terms or other comparable terminology.
Forward-looking statements are based upon management’s beliefs,
assumptions, and current expectations and may include comments as
to the company’s beliefs and expectations as to future events and
trends affecting its business and are necessarily subject to
uncertainties, many of which are outside the control of the
company. The factors described under the headings "Forward-Looking
Statements" and "Risk Factors" in the company’s periodic filings
with the Securities and Exchange Commission, as well as other
factors, could cause actual results to differ materially from those
reflected or predicted in forward-looking statements. Although
management believes that the expectations reflected in the
forward-looking statements are reasonable, forward-looking
statements are not, and should not be relied upon as a guarantee of
future performance or results, nor will they necessarily prove to
be accurate indications of the times at which such performance or
results will be achieved. The forward-looking statements included
are made only as of the date of the statement. 3D Systems
undertakes no obligation to update or review any forward-looking
statements made by management or on its behalf, whether as a result
of future developments, subsequent events or circumstances or
otherwise, except as required by law.
About 3D Systems More than 35 years ago, 3D
Systems brought the innovation of 3D printing to the manufacturing
industry. Today, as the leading additive manufacturing solutions
partner, we bring innovation, performance, and reliability to every
interaction - empowering our customers to create products and
business models never before possible. Thanks to our unique
offering of hardware, software, materials, and services, each
application-specific solution is powered by the expertise of our
application engineers who collaborate with customers to transform
how they deliver their products and services. 3D Systems’ solutions
address a variety of advanced applications in healthcare and
industrial markets such as medical and dental, aerospace &
defense, automotive, and durable goods. More information on the
company is available at www.3dsystems.com.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/b7110d3d-7ff8-443a-898f-370d07c321a5
Investor Contact:
investor.relations@3dsystems.comMedia Contact:
press@3dsystems.com
3D Systems (NYSE:DDD)
Historical Stock Chart
From Apr 2024 to May 2024
3D Systems (NYSE:DDD)
Historical Stock Chart
From May 2023 to May 2024